Tempest Therapeutics
TPST
54 hedge funds and large institutions have $31.3M invested in Tempest Therapeutics in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 23 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
6.51% less ownership
Funds ownership: 62.82% → 56.31% (-6.5%)
14% less funds holding
Funds holding: 63 → 54 (-9)
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
56% less capital inflows, than outflows
Capital inflows: $3.14M | Capital outflows: $7.18M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
+$652K |
| 2 |
Avoro Capital Advisors
New York
|
+$453K |
| 3 |
Broadfin Capital
New York
|
+$398K |
| 4 |
Millennium Management
New York
|
+$326K |
| 5 |
Element Capital Management
New York
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.04M |
| 2 |
GMT Capital
Atlanta,
Georgia
|
-$1.42M |
| 3 |
State Street
Boston,
Massachusetts
|
-$656K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$385K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$249K |
TPST Hedge Fund Activity: Q2 2017 in Review
54 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2017, worth a combined $31.3M — down 25% from $41.9M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TPST and 14 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 9 added.
The largest buyer was Legal & General Group, adding an estimated $652K. The largest seller was BlackRock, cutting an estimated $2.04M.
- 54 institutional investors held Tempest Therapeutics (TPST) as of Q2 2017, down from 63 in Q1 2017.
- Funds reported $31.3M of Tempest Therapeutics stock for Q2 2017, down 25% quarter-over-quarter.
- 14 funds opened new Tempest Therapeutics positions in Q2 2017 and 23 closed out, a net change of -9 holders.
- The largest Tempest Therapeutics buyer in Q2 2017 was Legal & General Group, an estimated $652K added.
- The largest Tempest Therapeutics seller in Q2 2017 was BlackRock, an estimated $2.04M sold.
Based on aggregated 13F filings for Q2 2017.